SAREPTA THERAPEUTICS, INC. Debt Conversion, Converted Instrument, Amount
SAREPTA THERAPEUTICS, INC. (SRPT) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2024-12-31 was $91.57M.
- SAREPTA THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2024-09-30 was $1.00K.
- SAREPTA THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2024 was $105.76M, a 84.75% decline from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2023 was $693.38M.
- SAREPTA THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2022 was $0.00.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2024-12-31 | $91.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $91.57M derived: sum of 2 quarters · filed 2026-03-02 | $105.76M derived: sum of 3 quarters · filed 2026-03-02 | $105.76M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.19M derived: sum of 2 quarters · filed 2025-11-06 | $14.19M 10-Q · filed 2025-11-06 | $14.19M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $14.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $14.18M 10-Q · filed 2025-08-06 | $14.18M derived: sum of 3 quarters · filed 2026-03-02 | $14.18M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $693.38M 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $693.38M 10-Q · filed 2024-11-06 | $693.38M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $693.38M 10-Q · filed 2024-08-07 | $693.38M derived: sum of 3 quarters · filed 2025-02-28 | $693.38M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $693.38M 10-Q · filed 2024-05-01 | $693.38M derived: sum of 2 quarters · filed 2025-02-28 | $693.38M derived: sum of 3 quarters · filed 2025-02-28 | $693.38M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |